𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats

✍ Scribed by Avantika Barve; Chi Chen; Vidya Hebbar; Joseph Desiderio; Constance Lay-Lay Saw; Ah-Ng Kong


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
155 KB
Volume
30
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The purpose of this study was to compare the hepatic and small intestinal metabolism, and to examine bioavailability and gastro‐intestinal first‐pass effects, of kaempferol in rats. Liver and small intestinal microsomes fortified with either NADPH or UDPGA were incubated with varying concentrations of kaempferol for up to 120 min. Based on the values of the kinetic constants (K~m~ and V~max~), the propensity for UDPGA‐dependent conjugation compared with NADPH‐dependent oxidative metabolism was higher for both hepatic and small intestinal microsomes. Male Sprague‐Dawley rats were administered kaempferol intravenously (i.v.) (10, 25 mg/kg) or orally (100, 250 mg/kg). Gastro‐intestinal first‐pass effects were observed by collecting portal blood after oral administration of 100 mg/kg kaempferol. Pharmacokinetic parameters were obtained by non‐compartmental analysis using WinNonlin. After i.v. administration, the plasma concentration–time profiles for 10 and 25 mg/kg were consistent with high clearance (∼3 L/hr/kg) and large volumes of distribution (8–12 L/hr/kg). The disposition was characterized by a terminal half‐life value of 3–4 h. After oral administration the plasma concentration–time profiles demonstrated fairly rapid absorption (t~max~∼1–2 h). The area under the curve (AUC) values after i.v. and oral doses increased approximately proportional to the dose. The bioavailability (F) was poor at ∼2%. Analysis of portal plasma after oral administration revealed low to moderate absorption. Taken together, the low F of kaempferol is attributed in part to extensive first‐pass metabolism by glucuronidation and other metabolic pathways in the gut and in the liver. Copyright © 2009 John Wiley & Sons, Ltd.


📜 SIMILAR VOLUMES


Pharmacokinetics and bioavailability of
✍ R. Obach; J. Pruñonosa; A. Menargues; M. Nomen; J. Vallès 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 467 KB 👁 1 views

In a pharmacokinetic study, 15, 30, 60, and 150 mg kg-' intravenous and oral doses of methocarbamol were administered to rats. Differences observed in plasma clearance values, i.e. 0~0203,0~0156,0~0123, and 0-0085 1 kg-' min-' for 15,30,60, and 150 mg kg-', respectively, suggested a dosedependent ph

Oral and rectal nalbuphine bioavailabili
✍ Bruce J. Aungst; Gilbert Lam; Eli Shefter 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 370 KB 👁 2 views

The disposition of the narcotic antagonist/analgesic nalbuphine after i.v., oral, and rectal dosing was evaluated in rats and dogs. In both species nalbuphine had high systemic clearance and low oral bioavailability as a result of extensive first-pass metabolism. Administration to a closed 2 cm leng

Pharmacokinetics and bioavailability of
✍ A. N. J. A. De Groot; T. B. Vree; Y. A. Hekster; M. Van Den Biggelaar-Martea; P. 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 380 KB 👁 2 views

The aim of this investigation was to assess the pharmacokinetics and bioavailability of ergometrine in six human male subjects after an oral dose of 0.200 mg and after an intravenous dose of 0.075 mg of ergometrine maleate. A large variation in bioavailability of between 34% and 117% in the six volu

Pharmacokinetics of oral L-isoidide mono
✍ Tsang-Bin Tzeng; Ho-Leung Fung 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 290 KB 👁 2 views

L-isoidide mononitrate (L-IIMN) is the most potent mononitrate vasodilator described so far in the literature. Since other mononitrates, such as isosorbide-Smononitrate and isosorbide-2-mononitrate, have been shown not to be subject to first-pass metabolism, we examined the pharmacokinetics of L-IIM